Selected article for: "adaptive innate and control trial"
Author: Meyerowitz, Eric A; Sen, Pritha; Schoenfeld, Sara R; Neilan, Tomas G; Frigault, Matthew J; Stone, John H; Kim, Arthur Y; Mansour, Michael K
Title: Immunomodulation as Treatment for Severe COVID-19: a systematic review of current modalities and future directions
  • Cord-id: d336tcts
  • Document date: 2020_11_20
    • ID: d336tcts
    Snippet: In SARS-CoV-2 infection, the viral load peaks early setting off a cascade of immune dysregulation that persists well after viral clearance. Severe COVID-19 is marked by aberrant innate and adaptive immune responses with an abnormal cytokine profile and a prolonged illness course with multisystem organ dysfunction. Antiviral treatments have yet to show benefit later in critical illness. Taken together, this raises the concern that a purely antiviral treatment approach may be insufficient. A numbe
    Document: In SARS-CoV-2 infection, the viral load peaks early setting off a cascade of immune dysregulation that persists well after viral clearance. Severe COVID-19 is marked by aberrant innate and adaptive immune responses with an abnormal cytokine profile and a prolonged illness course with multisystem organ dysfunction. Antiviral treatments have yet to show benefit later in critical illness. Taken together, this raises the concern that a purely antiviral treatment approach may be insufficient. A number of immunomodulatory strategies are being tested, including corticosteroids, cytokine and anti-cytokine therapies, small molecule inhibitors, and cellular therapeutics. The only drug to date to show a mortality benefit for COVID-19 in a randomized control trial is dexamethasone, but there remains uncertainty about which patients may benefit most and longer-term complications including secondary infections. Here we review the immune dysregulation of severe COVID-19, the existing data behind various immunomodulatory strategies, and consider future directions of study.

    Search related documents:
    Co phrase search for related documents
    • adaptive immune system and administration timing: 1
    • adaptive immune system and macrophage activation: 1, 2, 3, 4, 5
    • adaptive immune system innate and administration timing: 1
    • adaptive immune system innate and macrophage activation: 1, 2, 3, 4
    • administration timing and lopinavir ritonavir: 1, 2, 3
    • administration timing and lopinavir ritonavir ribavirin: 1
    • administration timing and lopinavir ritonavir ribavirin interferon: 1
    • lopinavir ritonavir and low incidence: 1
    • lopinavir ritonavir and low mortality: 1, 2, 3, 4, 5, 6, 7, 8
    • lopinavir ritonavir ribavirin and low mortality: 1
    • lopinavir ritonavir ribavirin interferon and low mortality: 1